We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
Turnover
53.26%
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+12.32%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$210M
AUM Growth
+$31.7M
(+18%)
Cap. Flow
-$9.22M
Cap. Flow
% of AUM
-4.38%
Top 10 Holdings %
Top 10 Hldgs %
41.52%
Holding
75
New
29
Increased
9
Reduced
14
Closed
17
Avg Time Held Equity + Options
0.3
years
Top 10 Avg Time Held Equity + Options
0.4
years
Top 20 Avg Time Held Equity + Options
0.4
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.6
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HCA Healthcare
HCA
|
+$5.11M |
| 2 |
Avanos Medical
AVNS
|
+$3.8M |
| 3 |
Revvity
RVTY
|
+$3.35M |
| 4 |
ELGX
Endologix Inc
ELGX
|
+$2.9M |
| 5 |
NEVRO CORP.
NVRO
|
+$2.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$7.56M |
| 2 |
GSK
GSK
|
+$6.33M |
| 3 |
Cardinal Health
CAH
|
+$4.73M |
| 4 |
Puma Biotechnology
PBYI
|
+$4.48M |
| 5 |
Sanofi
SNY
|
+$4.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.95% |
| 2 | Miscellaneous | 37.36% |
| 3 | Financials | 3.75% |
| 4 | Industrials | 2.24% |
| 5 | Technology | 0.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
PUT
Regeneron Pharmaceuticals
REGN
$81.3B
| $3.44M | 1.63% |
+7,000
| New | +$3.06M |
2017 Q2
0 quarters
|
|
27
PUT
Eli Lilly
LLY
$1.12T
| $3.29M | 1.56% |
+40,000
| New | +$3.26M |
2017 Q2
0 quarters
|
|
|
28
Eli Lilly
LLY
$1.12T
| $2.75M | 1.31% |
33,473
-24,313
| -42% | -$1.98M |
2016 Q4
2 quarters
|
|
29
Smith & Nephew
SNN
$12.1B
| $2.69M | 1.28% |
77,244
| – | – |
2017 Q1
1 quarter
|
|
30
Medtronic
MDT
$121B
| $2.66M | 1.27% |
30,000
| – | – |
2017 Q1
1 quarter
|
|
|
31
PUT
HCA Healthcare
HCA
$99.2B
| $2.62M | 1.24% |
+30,000
| New | +$2.54M |
2017 Q2
0 quarters
|
|
32
Elevance Health
ELV
$93.3B
| $2.59M | 1.23% |
+13,767
| New | +$2.47M |
2017 Q2
0 quarters
|
|
|
MZOR
33
DELISTED
Mazor Robotics Ltd.
MZOR
| $2.56M | 1.22% |
73,948
+42,483
| +135% | +$1.52M |
2017 Q1
1 quarter
|
|
|
NTUS
34
DELISTED
Natus Medical Inc
NTUS
| $2.54M | 1.21% |
+68,095
| New | +$2.46M |
2017 Q2
0 quarters
|
|
|
35
DELISTED
NEVRO CORP.
NVRO
| $2.48M | 1.18% |
+33,250
| New | +$2.66M |
2017 Q2
0 quarters
|
|
|
LMNX
36
DELISTED
Luminex Corp
LMNX
| $2.45M | 1.16% |
+115,979
| New | +$2.32M |
2017 Q2
0 quarters
|
|
|
ELGX
37
DELISTED
Endologix Inc
ELGX
| $2.4M | 1.14% |
+49,306
| New | +$2.9M |
2017 Q2
0 quarters
|
|
38
DELISTED
ChemoCentryx, Inc.
CCXI
| $2.29M | 1.09% |
244,850
-49,300
| -17% | -$362K |
2016 Q2
4 quarters
|
|
|
VRAY
39
DELISTED
ViewRay, Inc.
VRAY
| $2.03M | 0.97% |
+313,947
| New | +$2.1M |
2017 Q2
0 quarters
|
|
40
PUT
Penumbra
PEN
$12.6B
| $1.75M | 0.83% |
+20,000
| New | +$1.7M |
2017 Q2
0 quarters
|
|
41
PUT
Acadia Pharmaceuticals
ACAD
$3.31B
| $1.67M | 0.8% |
+60,000
| New | +$1.79M |
2017 Q2
0 quarters
|
|
42
Gyre Therapeutics
GYRE
$651M
| $1.64M | 0.78% |
+47,090
| New | +$1.69M |
2017 Q2
0 quarters
|
|
43
PUT
Medifast
MED
$133M
| $1.6M | 0.76% |
+38,500
| New | +$1.67M |
2017 Q2
0 quarters
|
|
|
VCRA
44
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $1.48M | 0.7% |
56,106
+6,235
| +13% | +$160K |
2017 Q1
1 quarter
|
|
|
ZYNE
45
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $1.19M | 0.57% |
+70,300
| New | +$1.4M |
2017 Q2
0 quarters
|
|
|
CLVS
46
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.17M | 0.56% |
+12,500
| New | +$765K |
2017 Q2
0 quarters
|
|
|
ARNA
47
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $1.17M | 0.56% |
+69,352
| New | +$951K |
2017 Q2
0 quarters
|
|
|
STDY
48
DELISTED
SteadyMed Ltd
STDY
| $1.06M | 0.5% |
+168,000
| New | +$1.14M |
2017 Q2
0 quarters
|
|
|
AVDL
49
DELISTED
Avadel Pharmaceuticals
AVDL
| $1.01M | 0.48% |
91,413
| – | – |
2016 Q4
2 quarters
|
|
50
Axsome Therapeutics
AXSM
$8.26B
| $880K | 0.42% |
160,000
-50,000
| -24% | -$209K |
2017 Q1
1 quarter
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q2 2017 Portfolio in Review
As of Q2 2017, Sio Capital Management held 75 positions worth $210M, up 18% from $179M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Sio Capital Management withdrew a net $9.22M in Q2 2017, closing 17 positions and reducing 14 holdings. Its most notable exit was Biogen, an estimated $7.56M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 66% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Sio Capital Management opened a new position in HCA Healthcare worth $5.27M.
- Sio Capital Management's largest Q2 2017 buy was HCA Healthcare: 60,420 shares worth $5.27M.
- Sio Capital Management added most to Aetna Inc in Q2 2017, an estimated $2.11M increase.
- Sio Capital Management's biggest Q2 2017 reduction was GSK, cutting an estimated $6.33M.
- Sio Capital Management fully exited Biogen in Q2 2017, selling an estimated $7.56M.
- Sio Capital Management's ten largest holdings make up 42% of its $210M portfolio in Q2 2017.
- Sio Capital Management opened 29 new positions and closed 17 in Q2 2017.
- Sio Capital Management's portfolio value rose 18% quarter-over-quarter to $210M.
Based on Sio Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.